The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
ping guo suan shu ni ti ni jiao nang
Author(s): 
Pages: 283-285
Year: Issue:  4
Journal: Chinese Journal of New Drugs

Keyword:  舒尼替尼 酪氨酸激酶抑制剂 胃肠间质瘤 肾细胞癌;
Abstract: [通用名称]sunitinib malate capsules,苹果酸舒尼替尼胶囊[商品名]Sutent,索坦[化学名称](Z)-N-[2-(二乙胺基)乙基-5-[(5-氟-2-氧代-1,2-二氢-3H-吲哚-3-亚基)甲基]-2,4-二甲[性基状-3]-氨甲酰-1H-吡咯苹果酸盐。黄色至橙色的颗粒。[药理毒理]药理作用:本品是一个小分子多靶点(多种受体)的酪氨酸激酶抑制剂,包括血小板衍生生长因子受体(PDGFRα和PDGFRβ)、血管内皮生长因子受体(VEGFR1,VEGFR2和VEGFR3)、干细胞因子受体(KIT)、Fms样酪氨酸激酶-3(FLT3)、1型集落刺激因子受体(CSF-1R)


Related Articles
loading...